IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $267.00.

Several analysts recently issued reports on the stock. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. The Goldman Sachs Group assumed coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective on the stock. Morgan Stanley boosted their target price on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada assumed coverage on IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective on the stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IQV. SS&H Financial Advisors Inc. purchased a new stake in IQVIA during the second quarter worth approximately $235,000. Sanctuary Advisors LLC purchased a new stake in shares of IQVIA during the 2nd quarter worth approximately $803,000. Brown Financial Advisors acquired a new position in shares of IQVIA in the 2nd quarter valued at $642,000. Dana Investment Advisors Inc. grew its position in shares of IQVIA by 7.4% in the 2nd quarter. Dana Investment Advisors Inc. now owns 87,145 shares of the medical research company’s stock valued at $18,426,000 after buying an additional 6,019 shares during the last quarter. Finally, Cetera Investment Advisers raised its stake in IQVIA by 3.3% during the 2nd quarter. Cetera Investment Advisers now owns 71,602 shares of the medical research company’s stock worth $15,140,000 after acquiring an additional 2,272 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV opened at $242.12 on Monday. The company’s 50-day moving average is $240.60 and its two-hundred day moving average is $233.94. IQVIA has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The firm has a market capitalization of $44.14 billion, a price-to-earnings ratio of 33.08, a PEG ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same period in the prior year, the business posted $2.22 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. Analysts forecast that IQVIA will post 10.25 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.